Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report [0.03%]
克唑替尼耐药后免疫治疗响应的肺肉瘤样癌跳跃14号外显子缺失MET突变一例报告
Ling Gu,Xiaoying Wei,Zixiang Zhang et al.
Ling Gu et al.
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC) with poor prognosis. The skipping mutation in exon 14 of MET, an oncogenic driver of NSCLC, occurs more frequently in PSC than other subtypes. Tre...
Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study [0.03%]
安罗替尼治疗广泛期小细胞肺癌患者真实世界探索性研究疗效和安全性分析：化疗后疾病进展患者
Yonghui Li,Zhenqing Sun,Wei Sun et al.
Yonghui Li et al.
Background: Anlotinib demonstrated promising efficacy for patients with extensive-stage small-cell lung cancer (ES-SCLC) in clinical trials. However, the real-world evidence of anlotinib monotherapy in ES-SCLC was still l...
PIK3CA Mutations in Diffuse Gliomas: An Update on Molecular Stratification, Prognosis, Recurrence, and Aggressiveness [0.03%]
PIK3CA突变在弥漫性胶质瘤中的研究进展：分子分型、预后、复发及侵袭性的再评估
Cheila Brito,Ana Tomás,Ana Azevedo et al.
Cheila Brito et al.
Introduction: PIK3CA is one of the most mutated oncogenes in solid tumors. In breast cancer (ER-positive, HER2-negative), these events represent a predictive biomarker of response to alpelisib. In glioblastomas (GBM), PIK...
Is Cytoreductive Surgery Possible in Cervical Cancer Peritoneal Carcinomatosis? [0.03%]
宫颈癌腹膜癌化疗后盆腔细胞减灭术的可行性研究
Ozgul Duzgun,Murat Kalin
Ozgul Duzgun
Background: The number of cases of cervical cancer with recurrence and peritoneal carcinomatosis is limited. In our study, we aimed to present the results of cytoreductive surgery hyperthermic intraperitoneal chemotherapy...
Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study [0.03%]
GSTP1多态性对晚期NSCLC患者一线贝伐珠单抗治疗临床疗效的影响：一项回顾性真实世界研究
Fei Han,Hanji Tian,Baoli Jin et al.
Fei Han et al.
Background: This study was to investigate the influence of GSTP1 gene polymorphism on the clinical outcomes of patients with advanced non-small-cell lung cancer (NSCLC) receiving first-line bevacizumab plus chemotherapy r...
Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development [0.03%]
免疫检查点抑制剂在非小细胞肺癌中引起的神经不良事件：当前的视角和新进展
Ke Cheng,Yuqing Wang,Yuwen Zhou et al.
Ke Cheng et al.
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple malignancies, especially in non-small cell lung cancer (NSCLC). With the extensive application of ICIs in clinical practice, clinicians have to manage their t...
Nomogram Incorporating Contrast-Enhanced Ultrasonography Predicting Time to the Development of Castration-Resistant Prostate Cancer [0.03%]
包含对比增强超声的列线图预测去势抵抗性前列腺癌进展的时间
Yun-Xin Zhao,Guang-Li Yao,Jian Sun et al.
Yun-Xin Zhao et al.
Background: It is valuable to predict the time to the development of castration-resistant prostate cancer (CRPC) in patients with advanced prostate cancer (PCa). This study aimed to build and validate a nomogram incorpora...
Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma [0.03%]
同期放化疗联合周低剂量顺铂治疗日本头颈部鳞状细胞癌患者
Shogo Shinohara,Shinji Takebayashi,Kiyomi Hamaguchi et al.
Shogo Shinohara et al.
Background: Concurrent chemoradiotherapy (CCRT) with tri-weekly high-dose cisplatin (HDC) is considered the standard regimen. However, due to significant toxicity, various weekly low-dose schedules have been increasingly ...
Logan P Rhea,Jeanny B Aragon-Ching
Logan P Rhea
Immune checkpoint inhibitors have revolutionized the treatment of bladder urothelial cancers and have wide application in almost all disease states. Although several drugs have initially been shown to be beneficial in the second-line metast...
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study [0.03%]
COVID-19爆发对癌症患者临床结果的影响:一项回顾性研究
Sebastiano Buti,Fabiana Perrone,Teresa Zielli et al.
Sebastiano Buti et al.
Background: Coronavirus disease (COVID-19), an acute respiratory syndrome caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has rapidly spread worldwide, significantly affecting the outcome of ...